880 related articles for article (PubMed ID: 14716738)
21. A model for the turnover of dihydrotestosterone in the presence of the irreversible 5 alpha-reductase inhibitors GI198745 and finasteride.
Gisleskog PO; Hermann D; Hammarlund-Udenaes M; Karlsson MO
Clin Pharmacol Ther; 1998 Dec; 64(6):636-47. PubMed ID: 9871428
[TBL] [Abstract][Full Text] [Related]
22. Androgen receptor activity at the prostate specific antigen locus: steroidal and non-steroidal mechanisms.
Jia L; Kim J; Shen H; Clark PE; Tilley WD; Coetzee GA
Mol Cancer Res; 2003 Mar; 1(5):385-92. PubMed ID: 12651911
[TBL] [Abstract][Full Text] [Related]
23. Novel steroid receptor phyto-modulator compound a inhibits growth and survival of prostate cancer cells.
Yemelyanov A; Czwornog J; Gera L; Joshi S; Chatterton RT; Budunova I
Cancer Res; 2008 Jun; 68(12):4763-73. PubMed ID: 18559523
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of LncaP prostate cancer cells by means of androgen receptor antisense oligonucleotides.
Eder IE; Culig Z; Ramoner R; Thurnher M; Putz T; Nessler-Menardi C; Tiefenthaler M; Bartsch G; Klocker H
Cancer Gene Ther; 2000 Jul; 7(7):997-1007. PubMed ID: 10917202
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of fatty acid synthase activity in prostate cancer cells by dutasteride.
Schmidt LJ; Ballman KV; Tindall DJ
Prostate; 2007 Jul; 67(10):1111-20. PubMed ID: 17477363
[TBL] [Abstract][Full Text] [Related]
26. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride.
Olsen EA; Hordinsky M; Whiting D; Stough D; Hobbs S; Ellis ML; Wilson T; Rittmaster RS;
J Am Acad Dermatol; 2006 Dec; 55(6):1014-23. PubMed ID: 17110217
[TBL] [Abstract][Full Text] [Related]
27. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
[TBL] [Abstract][Full Text] [Related]
28. New steroidal 17β-carboxy derivatives present anti-5α-reductase activity and anti-proliferative effects in a human androgen-responsive prostate cancer cell line.
Amaral C; Varela C; Correia-da-Silva G; Tavares da Silva E; Carvalho RA; Costa SC; Cunha SC; Fernandes JO; Teixeira N; Roleira FM
Biochimie; 2013 Nov; 95(11):2097-106. PubMed ID: 23933094
[TBL] [Abstract][Full Text] [Related]
29. Importance of the intracrine metabolism of adrenal androgens in androgen-dependent prostate cancer.
Suzuki K; Nishiyama T; Hara N; Yamana K; Takahashi K; Labrie F
Prostate Cancer Prostatic Dis; 2007; 10(3):301-6. PubMed ID: 17387321
[TBL] [Abstract][Full Text] [Related]
30. Antiandrogenic and growth inhibitory effects of ring-substituted analogs of 3,3'-diindolylmethane (ring-DIMs) in hormone-responsive LNCaP human prostate cancer cells.
Abdelbaqi K; Lack N; Guns ET; Kotha L; Safe S; Sanderson JT
Prostate; 2011 Sep; 71(13):1401-12. PubMed ID: 21321979
[TBL] [Abstract][Full Text] [Related]
31. Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer.
Thomas LN; Douglas RC; Lazier CB; Too CK; Rittmaster RS; Tindall DJ
Eur Urol; 2008 Feb; 53(2):244-52. PubMed ID: 18006217
[TBL] [Abstract][Full Text] [Related]
32. 19-nor-10-azasteroids: a novel class of inhibitors for human steroid 5alpha-reductases 1 and 2.
Guarna A; Belle C; Machetti F; Occhiato EG; Payne AH; Cassiani C; Comerci A; Danza G; De Bellis A; Dini S; Marrucci A; Serio M
J Med Chem; 1997 Mar; 40(7):1112-29. PubMed ID: 9089333
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
[TBL] [Abstract][Full Text] [Related]
34. Differential expression of steroid 5alpha-reductase isozymes and association with disease severity and angiogenic genes predict their biological role in prostate cancer.
Das K; Lorena PD; Ng LK; Lim D; Shen L; Siow WY; Teh M; Reichardt JK; Salto-Tellez M
Endocr Relat Cancer; 2010 Sep; 17(3):757-70. PubMed ID: 20519274
[TBL] [Abstract][Full Text] [Related]
35. Piper cubeba targets multiple aspects of the androgen-signalling pathway. A potential phytotherapy against prostate cancer growth?
Yam J; Kreuter M; Drewe J
Planta Med; 2008 Jan; 74(1):33-8. PubMed ID: 18080233
[TBL] [Abstract][Full Text] [Related]
36. The role of transforming growth factor-beta1, -beta2, and -beta3 in androgen-responsive growth of NRP-152 rat prostatic epithelial cells.
Lucia MS; Sporn MB; Roberts AB; Stewart LV; Danielpour D
J Cell Physiol; 1998 May; 175(2):184-92. PubMed ID: 9525477
[TBL] [Abstract][Full Text] [Related]
37. Piperazine-designed alpha 1A/alpha 1D-adrenoceptor blocker KMUP-1 and doxazosin provide down-regulation of androgen receptor and PSA in prostatic LNCaP cells growth and specifically in xenografts.
Liu CM; Lo YC; Tai MH; Wu BN; Wu WJ; Chou YH; Chai CY; Huang CH; Chen IJ
Prostate; 2009 May; 69(6):610-23. PubMed ID: 19143029
[TBL] [Abstract][Full Text] [Related]
38. The biological basis for the use of an anti-androgen and a 5-alpha-reductase inhibitor in the treatment of recurrent prostate cancer: Case report and review.
Wang LG; Mencher SK; McCarron JP; Ferrari AC
Oncol Rep; 2004 Jun; 11(6):1325-9. PubMed ID: 15138573
[TBL] [Abstract][Full Text] [Related]
39. Camptothecin disrupts androgen receptor signaling and suppresses prostate cancer cell growth.
Liu S; Yuan Y; Okumura Y; Shinkai N; Yamauchi H
Biochem Biophys Res Commun; 2010 Apr; 394(2):297-302. PubMed ID: 20206136
[TBL] [Abstract][Full Text] [Related]
40. Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5alpha-reductase.
Vis AN; Schröder FH
BJU Int; 2009 Nov; 104(9):1191-7. PubMed ID: 19624596
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]